TY - JOUR
T1 - To maintain or cease non-Vitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures
T2 - A review of evidence and recommendations
AU - Brennan, Yvonne
AU - Favaloro, Emmanuel J
AU - Curnow, Jennifer
N1 - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
PY - 2019/3
Y1 - 2019/3
N2 - For procedures associated with minimal bleeding risk, there are data and experience to support the practice of continuing vitamin K antagonists rather than interrupting therapy, to prevent exposing patients to the undue risk of developing thromboembolism during anticoagulation cessation. Despite the increasing use of non-vitamin K oral anticoagulants (NOACs), there is little evidence to guide the management of these drugs around minimal bleeding risk procedures. This review examines and discusses the major society guidelines and recommendations addressing the management of NOACs around minimal bleeding risk procedures. Additionally, it summarizes the existing evidence, and highlights the gaps in knowledge where evidence is not yet available. Finally, recommendations are made to assist the proceduralist deal with this area of limited evidence.
AB - For procedures associated with minimal bleeding risk, there are data and experience to support the practice of continuing vitamin K antagonists rather than interrupting therapy, to prevent exposing patients to the undue risk of developing thromboembolism during anticoagulation cessation. Despite the increasing use of non-vitamin K oral anticoagulants (NOACs), there is little evidence to guide the management of these drugs around minimal bleeding risk procedures. This review examines and discusses the major society guidelines and recommendations addressing the management of NOACs around minimal bleeding risk procedures. Additionally, it summarizes the existing evidence, and highlights the gaps in knowledge where evidence is not yet available. Finally, recommendations are made to assist the proceduralist deal with this area of limited evidence.
KW - Administration, Oral
KW - Anticoagulants/administration & dosage
KW - Atrial Fibrillation/drug therapy
KW - Hemorrhage/chemically induced
KW - Humans
KW - Practice Guidelines as Topic
KW - Risk Factors
KW - Venous Thromboembolism/prevention & control
KW - Vitamin K/antagonists & inhibitors
U2 - 10.1055/s-0039-1678719
DO - 10.1055/s-0039-1678719
M3 - Review article
C2 - 30743279
SN - 1098-9064
VL - 45
SP - 171
EP - 179
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
IS - 2
ER -